Humana Inc vs Payoneer Global Inc — how do they compare? Humana Inc trades at $429.8 (market cap $46.49B), while Payoneer Global Inc trades at $7.16 (market cap $2.43B). The key difference: Humana Inc is far larger — about 19.1× Payoneer Global Inc's market cap, and Humana Inc pays a 0.91% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Payoneer Global Inc for 61 Days on average.
| HUM | PAYO | |
|---|---|---|
Market Cap | $46.49B | $2.43B |
Volume | 2,567,704 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $409.85 | $7.18 |
52-Week Low | $163.67 | $4.27 |
Typical Hold Time | 53 Days | 61 Days |
Enterprise Value | $53.84B | $2.17B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Payoneer Global (PAYO) trades at $7.16, showing minimal daily movement with a 0.14% gain. The stock maintains a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, revenue grew to $821 million in 2025 with a 78% gross margin, but net income declined to $73 million. Recent news highlights the company's acquisition agreement with Nuvei and strategic expansion into India, while earnings show mixed quarterly performance with two misses and one beat in the last four quarters.
PAYO presents a mixed outlook with 60% analyst buy ratings supporting growth potential from international expansion and partnership renewals. However, declining profit margins, elevated P/E ratio of 51.18, and acquisition-related uncertainties pose significant risks. The stock's current technical strength contrasts with fundamental challenges, requiring careful monitoring of execution against growth initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →